Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple MyelomaInterventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: sargramostim; Biological: aldesleukin; Other: laboratory biomarker analysisSponsors: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)Active, not recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Myeloma | Research | Stem Cell Therapy | Stem Cells | Transplants | University of Washington | Vaccines